STOCK TITAN

Royalty Pharma: SCH plans $10.2M share sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Royalty Pharma plc reports that SCH Investment Partners LLC plans to sell 150,000 Class A ordinary shares, with an aggregate market value of $10,176,000 and an approximate sale date of November 17, 2026. SCH Investment Partners LLC is listed with an Officer relationship to Royalty Pharma. The shares were acquired from the issuer in a private transaction on May 13, 2024. The planned sale is connected to a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c).

Shares planned for sale 150,000 shares Approximate sale date: November 17, 2026
Aggregate market value $10,176,000 Shares planned for sale
Shares sold 100,000 shares September 22, 2026; gross proceeds were $5,846,972.43
Gross proceeds $5,846,972.43 Sale of 100,000 shares on September 22, 2026
Shares sold 100,000 shares August 18, 2026; gross proceeds were $5,991,122.91
Gross proceeds $5,991,122.91 Sale of 100,000 shares on August 18, 2026
Rule 10b5-1(c) regulatory
"selling plan dated March 20, 2026, which is intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What prior RPRX sales did SCH Investment Partners report?

It reported sales of 100,000 Class A ordinary shares on September 22, 2026, for gross proceeds of $5,846,972.43, and 100,000 shares on August 18, 2026, for gross proceeds of $5,991,122.91.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading